高级检索
当前位置: 首页 > 详情页

A novel nomogram for prognosis stratification in salvage liver transplantation: a national-wide study with propensity score matching analysis in China

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [2]Institute of Organ Transplantation, Zhejiang University, Hangzhou, China [3]Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [4]NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China [5]Zhejiang University School of Medicine, Hangzhou, China [6]Department of Hepatobiliary and Pancreatic Surgery, Affiliated Lishui Hospital, Zhejiang University School of Medicine, Lishui, China [7]National Center for Healthcare Quality Management in Liver Transplant, Hangzhou, China [8]Graduate School, Nanjing University of Chinese Medicine, Nanjing, China [9]Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China [10]Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China [11]Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China [12]Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [13]Department of Hepatobiliary and Pancreatic Surgery, Shulan Hospital of Hangzhou, Hangzhou, China
出处:
ISSN:

关键词: Salvage liver transplantation (SLT) nomogram primary liver transplantation (PLT) overall survival (OS) disease-free survival (DFS)

摘要:
Background: Salvage liver transplantation (SLT) has been reported to be an efficient treatment option for patients with recurrent hepatocellular carcinoma (HCC) after liver resection (LR). However, for recipients who underwent liver transplantation (LT) due to recurrent HCC after LR in China, the selection criteria are not well established. Methods: In this study, data from the China Liver Transplant Registry (CLTR) of 4244 LT performed from January 2015 to December 2019 were examined, including 3,498 primary liver transplantation (PLT) and 746 SLT recipients. Propensity score matching (PSM) analysis was used to minimize between-group imbalances. The overall survival (OS) and disease-free survival (DFS) between PLT and SLT in recipients fulfilling the Milan or Hangzhou criteria were compared based on the multivariate analysis, nomograms were plotted to further classify the SLT group into low-and high-risk groups. Results: In this study, the 1-, 3-and 5-year OS and DFS of SLT recipients fulfilling Milan criteria (OS, P=0.01; DFS, P<0.001) or Hangzhou criteria (OS, P=0.03; DFS, P=0.003) were significantly reduced when compared to that of PLT group after PSM analysis. Independent risk factors, including preoperative transarterial chemoembolization (TACE), alpha fetoprotein (AFP) level, tumor maximum size and tumor total diameter were selected to draw a prognostic nomogram. The low-risk SLT recipients (1-year, 95.34%; 3-year, 84.26%; 5-year, 77.20%) showed a comparable OS with PLT recipients fulfilling Hangzhou criteria (P=0.107). Conclusions: An optimal nomogram model for prognosis stratification and clinical decision guidance of SLT was established. The low-risk SLT recipients based on the nomograms showed comparable survival with those fulfilling Hangzhou criteria in PLT group.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 营养学 2 区 外科 3 区 胃肠肝病学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 营养学 2 区 外科 3 区 胃肠肝病学
JCR分区:
出版当年[2023]版:
Q1 GASTROENTEROLOGY & HEPATOLOGY Q1 NUTRITION & DIETETICS Q1 SURGERY
最新[2023]版:
Q1 GASTROENTEROLOGY & HEPATOLOGY Q1 NUTRITION & DIETETICS Q1 SURGERY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [2]Institute of Organ Transplantation, Zhejiang University, Hangzhou, China [3]Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [4]NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China
共同第一作者:
通讯作者:
通讯机构: [2]Institute of Organ Transplantation, Zhejiang University, Hangzhou, China [3]Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China [4]NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China [5]Zhejiang University School of Medicine, Hangzhou, China [7]National Center for Healthcare Quality Management in Liver Transplant, Hangzhou, China [10]Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China [11]Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China [12]Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [13]Department of Hepatobiliary and Pancreatic Surgery, Shulan Hospital of Hangzhou, Hangzhou, China [*1]Zhejiang University School of Medicine, Hangzhou 310058, China [*2]Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. [*3]Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China. [*4]Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu 610044, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Elevated pretreatment serum lactate dehydrogenase level predicts inferior overall survival and disease-free survival after resection of thymic carcinoma [2]Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) [3]Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations [4]The role of postoperative radiotherapy for stage I/II/III thymic tumor-results of the ChART retrospective database [5]High ANKZF1 expression is associated with poor overall survival and recurrence-free survival in colon cancer. [6]Epigenome-wide development and validation of a prognostic methylation score in intrahepatic cholangiocarcinoma based on machine learning strategies [7]Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers [8]Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials. [9]A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell lung cancer (NSCLC) [10]Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号